Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?
Yıl: 2022 Cilt: 38 Sayı: 1 Sayfa Aralığı: 60 - 66 Metin Dili: İngilizce DOI: 10.47717/turkjsurg.2022.5318 İndeks Tarihi: 31-10-2022
Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?
Öz: Objective: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays an important role in physiological and pathological angiogenesis of the thyroid. The aim of the current study was to determine the expression characteristics of VEGF in follicular cell-derived lesions of the thyroid and to assess whether a new entity noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is precancerous. Material and Methods: Patients diagnosed with 33 follicular adenomas (FA), 41 invasive follicular variant papillary thyroid cancer (IN-FVPTC), and 40 NIFTP in surgical resection materials were evaluated retrospectively. Immunostaining was performed on 5-μm paraffin tissue sections. The percentages of immunostaing for VEGF were evaluated on pathological materials. We used a percentage of labeled thyrocytes score (0, no labeling; 1, <30%; 2, 31-60%; 3, >60%) and an intensity score (0, no staining; 1, weak; 2, intermediate; 3, strong). The sum of two scores were accepted as the total score. Results: Mean ages of the FA, IN-FVPTC, and NIFTP groups were 44.7 ± 11.7 years, 46.9 ± 13.6 years, 43.2 ± 15.4 years, respectively and the mean VEGF immunostaining scores were 44.7 ± 29.3, 50.2 ± 32.54, 4 ± 26.3 respectively. Although there was no statistically significant difference (p= 0.347), the total score of the NIFTPs was higher than the scores of the FA (mean= 3.9 ± 1.8) and IN-FVPTC(mean= 4.3 ± 1.9) groups with a mean value of 4.6 ± 1.7. This result was remarkable. There was no statistically significant difference between tumor diameters and staining percentages (p= 0.750). Conclusion: Even if there were no statistical differences for VEGF immunostaining, it was high in NIFTPs. Since we know the role of VEGF in tumorigenesis, we can hypothesize that NIPTP can be precancerous. Our argue should be corroborated by a large prospective study.
Anahtar Kelime: Folikuler hücreden kaynaklanan tiroid neoplazilerinde ‘Vascular Endothelial Growth Factor’ ekspresyonu: NIFTP benign mi prekanseröz mü?
Öz: Giriş ve Amaç: Vasküler endotelyal büyüme faktörü (VEGF) tiroidin fizyolojik ve patolojik anjiyogenezinde önemli rol oynar. Çalışmamızın amacı tiroidin folikuler hücre kaynaklı lezyonlarının VEGF ekspresyon özelliklerini belirleyerek papiller yapıda çekirdek özellikleri gösteren noninvaziv foliküler tiroit neoplazi (NIFTP) lezyonlarının prekanseröz olup olmadığını bu yolla değerlendirmek. Gereç ve Yöntem: 33 folikuler adenom (FA), 41 invaziv folikuler varyant papiller tiroid kanseri ve 40 NIFTP tanısı olan hastanın tiroidektomi materyali retrospektif olarak değerlendirildi. 5-μm parafin kesitlerde VEGF immun boyama yapıldı. Belirlenen yüzdesel orana (boyanma yok; 0, %<30; 1, %31-60; 2, %>60; 3) ve boyanma yoğunluğuna göre (boyanma yok; 0, zayıf; 1 orta; 2, yoğun; 3) skorlama yapıldı. İki farklı skor kategorisinden total skor elde edildi. Bulgular: FA, İN- FVPTK ve NIFTP gruplarında ortalama yaş sırasıyla 44,7 ± 11.7, 46,9 ± 13,6, 43,2 ± 15,4 yıldı. VEGF immun boyanma yüzdesi ise sırayla 44,7 ± 29,3, 50,2 ± 32, 54,4 ± 26,3 bulundu. İstatistiki olarak anlamlı olmasa da (p= 0,347) NIFTP grubunda total skor ortalama 4,6 ± 1,7 değeri ile FA (ort= 3,9 ± 1,8) ve İN-FVPTK (ort= 4,3 ± 1,9) daha yüksekti. Bu sonuç dikkat çekiciydi. Tümör çapları ile VEGF boyanma yüzdeleri arasında istatistiki anlamlılık yoktu. Sonuç: İstatistiki anlamlılık olmasa da VEGF immun boyanma NIFTP lezyonlarda yüksek saptandı. VEGF’nin tümörogenezdeki rolü dikkate alındığında bu sonuç ‘NIFTP lezyonlar papiller tiroid kanserinin öncüsü olabilir mi?’ hipotezini desteklemektedir. Geniş kapsamlı çalışmalar yapılması NIFTP lezyonların patolojik yerini anlamada bu hipoteze katkı sağlayabilecektir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Mehrzad R, Nishino M, Connolly J, Wang H, Mowschenson P, Hasselgren PO. The relationship between the follicular variant of papillary thyroid cancer and follicular adenomas. Surgery 2016; 159: 1396-406. https://doi.org/10.1016/j.surg.2015.11.026
- 2. Vasko VV, Gaudart J, Allasia C, Savchenko V, Cristofaro J, Saji M, et al. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur J Endocrinol 2004; 151: 779-86. https://doi.org/10.1530/eje.0.1510779
- 3. Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 2001; 86: 3211-6. https://doi. org/10.1210/jc.86.7.3211
- 4. Tallini G, Michael RT, Ghossein RA. The history of the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2017; 102: 15- 22. https://doi.org/10.1210/jc.2016-2976
- 5. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LH, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016; 2: 1023-9. https://doi.org/10.1001/jamaoncol.2016.0386
- 6. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli B, Doherty GM, et al. American Thyroid Association Guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid 2017; 27: 481-3. https://doi.org/10.1089/thy.2016.0628
- 7. Nikiforov YE, Baloch ZW, Hodak SP, Giordano TJ, Lloyd RV, et al. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features. JAMA Oncol 2018; 4: 1125-6. https://doi.org/10.1001/jamaoncol.2018.1446
- 8. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5. https://doi. org/10.1126/science.6823562
- 9. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000 ;55: 15-35.
- 10. Turner HE, Harris AL, Melmed S, Wass JA. Angiogenesis in endocrine tumors Endocr Rev 2003; 24: 600-32. https://doi.org/10.1210/er.2002- 0008
- 11. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 1999; 161: 41-9. https://doi.org/10.1677/joe.0.1610041
- 12. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4. https://doi.org/10.1038/386671a0
- 13. Arbiser JL. Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: evidence of predictable and reproducible patterns of synergy in diverse neoplasms. Semin Cancer Biol 2014; 14: 81-91. https://doi.org/10.1016/j.semcancer.2003.09.013
- 14. Gulubova M, Ivanova K, Ananiev J, Gerenova J, Zdraveski A, Stoyanoz H, et al. VEGF expression, microvessel density and dendritic cell decrease in thyroid cancer. Biotechnol Biotechnol Equip 2014; 28: 508-17. https://doi.org/10.1080/13102818.2014.909151
- 15. Holmes DR, Zachary L. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease Genome Biol 2005; 6: 209. https://doi.org/10.1186/gb-2005-6-2-209
- 16. Krilleke D, Ng YS, Shima DT. The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure- function study. Biochem Soc Trans 2009; 37: 1201-6. https://doi. org/10.1042/BST0371201
- 17. Andreozzi M, Quagliata L, Gsponer JR, Ruiz C, Vuaroqueaux V, Castori- Eppenberger S, et al. VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities Angiogenesis 2014; 17: 519-27. https://doi.org/10.1007/s10456-013- 9396-z
- 18. Lloyd RV, Osamura RY, Klöppel G, Rosai J. World Health Organization. WHO Classification of Tumours of Endocrine Organs. IARC. 4th Lyon; 2017 p: 66-90.
- 19. Johnson DN, Furtado LV, Long BC, Zhen JC, Wurst M, Mujacic I, et al. Noninvasive follicular thyroid neoplasms with papillary-like nuclear features are genetically and biologically similar to adenomatous nodules and distinct from papillary thyroid carcinomas with extensive follicular growth. Arch Pathol Lab Med 2018; 142: 838-50. https://doi. org/10.5858/arpa.2017-0118-OA
- 20. Kim M, Jeon MJ, Oh HS, Park S, Kim TY, Shong YK, et al. BRAF and RAS mutational status in noninvasive follicular thyroid neoplasm with papillary- like nuclear features and invasive subtype of encapsulated follicular variant of papillary thyroid carcinoma in Korea. Thyroid 2018; 28: 504-10. https://doi.org/10.1089/thy.2017.0382
- 21. Song YS, Won JK, Yoo SK, Jung KC, Kim MJ, Kim SJ, et al. Comprehensive transcriptomic and genomic profiling of subtypes of follicular variant of papillary thyroid carcinoma. Thyroid 2018; 28: 1468-78. https:// doi.org/10.1089/thy.2018.0198
- 22. Giannini R, Ugolini C, Poma AM, Urpi M, Niccoli C, Elisei R, et al. Identification of two distinct molecular subtypes of non-invasive follicular neoplasm with papillary-like nuclear features by digital RNA counting. Thyroid 2017; 27: 1267-76. https://doi.org/10.1089/thy.2016.0605
- 23. Parente DN, Kluijfhout WP, Bongers PJ, Verzijl R, Devon KM, Rotstein SE, et al. Clinical safety of renaming encapsulated follicular variant of papillary thyroid carcinoma: Is NIFTP truly benign? World J Surg 2018; 42: 321-6. https://doi.org/10.1007/s00268-017-4182-5
- 24. Cho U, Mete O, Kim MH, Bae JS, Jung CK. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features. Mod Pathol 2017; 30: 810-25. https://doi.org/10.1038/modpathol. 2017.9
- 25. Fenton C, Patel A, Dinauer C, Tuttle RM, Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000; 10: 349-57. https://doi.org/10.1089/thy.2000.10.349
- 26. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 656-8. https://doi.org/10.1210/ jcem.86.2.7226
- 27. Ria R, Prete F, Melaccio A, Salterall I, Solimando AG, Gurrado A, et al. Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: Potential for new biomarkers? Surgery 2020; 6060: (20): 30177-X.
- 28. Baloch ZW, LiVolsi VA. Our approach to follicular-patterned lesions of the thyroid. J Clin Pathol 2007; 60: 244-50. https://doi.org/10.1136/ jcp.2006.038604
| APA | Kurtulmus N, Tokat F, düren m, Kaya H, Ertas B, ince u (2022). Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. , 60 - 66. 10.47717/turkjsurg.2022.5318 |
| Chicago | Kurtulmus Neslihan,Tokat Fatma,düren mete,Kaya Hakan,Ertas Burak,ince umit Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. (2022): 60 - 66. 10.47717/turkjsurg.2022.5318 |
| MLA | Kurtulmus Neslihan,Tokat Fatma,düren mete,Kaya Hakan,Ertas Burak,ince umit Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. , 2022, ss.60 - 66. 10.47717/turkjsurg.2022.5318 |
| AMA | Kurtulmus N,Tokat F,düren m,Kaya H,Ertas B,ince u Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. . 2022; 60 - 66. 10.47717/turkjsurg.2022.5318 |
| Vancouver | Kurtulmus N,Tokat F,düren m,Kaya H,Ertas B,ince u Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. . 2022; 60 - 66. 10.47717/turkjsurg.2022.5318 |
| IEEE | Kurtulmus N,Tokat F,düren m,Kaya H,Ertas B,ince u "Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?." , ss.60 - 66, 2022. 10.47717/turkjsurg.2022.5318 |
| ISNAD | Kurtulmus, Neslihan vd. "Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?". (2022), 60-66. https://doi.org/10.47717/turkjsurg.2022.5318 |
| APA | Kurtulmus N, Tokat F, düren m, Kaya H, Ertas B, ince u (2022). Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. Turkish Journal of Surgery, 38(1), 60 - 66. 10.47717/turkjsurg.2022.5318 |
| Chicago | Kurtulmus Neslihan,Tokat Fatma,düren mete,Kaya Hakan,Ertas Burak,ince umit Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. Turkish Journal of Surgery 38, no.1 (2022): 60 - 66. 10.47717/turkjsurg.2022.5318 |
| MLA | Kurtulmus Neslihan,Tokat Fatma,düren mete,Kaya Hakan,Ertas Burak,ince umit Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. Turkish Journal of Surgery, vol.38, no.1, 2022, ss.60 - 66. 10.47717/turkjsurg.2022.5318 |
| AMA | Kurtulmus N,Tokat F,düren m,Kaya H,Ertas B,ince u Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. Turkish Journal of Surgery. 2022; 38(1): 60 - 66. 10.47717/turkjsurg.2022.5318 |
| Vancouver | Kurtulmus N,Tokat F,düren m,Kaya H,Ertas B,ince u Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?. Turkish Journal of Surgery. 2022; 38(1): 60 - 66. 10.47717/turkjsurg.2022.5318 |
| IEEE | Kurtulmus N,Tokat F,düren m,Kaya H,Ertas B,ince u "Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?." Turkish Journal of Surgery, 38, ss.60 - 66, 2022. 10.47717/turkjsurg.2022.5318 |
| ISNAD | Kurtulmus, Neslihan vd. "Expression of vascular endothelial growth factor in follicular cell-derived lesions of the thyroid: Is NIFTP benign or precancerous?". Turkish Journal of Surgery 38/1 (2022), 60-66. https://doi.org/10.47717/turkjsurg.2022.5318 |
